Nivolumab-ipilimumab combination demonstrates antitumor activity in prostate cancer subset. A combination of nivolumab and ipilimumab induced significant antitumor activity among men with metastatic castration-resistant prostate cancer and a positive immunogenic signature, according to results of the phase 2 NEPTUNES trial.
Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
Nivolumab-ipilimumab combo demonstrated significant antitumor activity in PCA
Researchers presented the data at the virtual American Association for Cancer Research Annual Meeting. The NEPTUNES study has demonstrated a 29% response rate in patients with quite heavily pretreated metastatic prostate cancer. In patients with either mismatch repair deficiency or BRCA1/BRCA2 this response was enriched to 80%, and in patients with high inflammatory infiltrate the response rate was 30%, this compares with only a 6% response rate for patients with other defects in DNA damage repair. The analysis included 36 men with metastatic CRPC (median age, 66.5 years; range: 50-77) who experienced disease progression after at least one line of therapy and had a positive immunogenic signature.
